Derangements of intravascular remodeling of lipoproteins in type 2 diabetes mellitus: Consequences for atherosclerosis development

Current Diabetes Reports

Volumn 8, Issue 1, 2008, Pages 65-70

  Dallinga Thie, Geesje M ^a   Dullaart, Robin P F ^b   van Tol, Arie ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; APOLIPOPROTEIN; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOKINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PHOSPHOLIPID TRANSFER PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ARTERY INTIMA PROLIFERATION; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL ESTERIFICATION; CHOLESTEROL TRANSPORT; DIABETIC ANGIOPATHY; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MACROPHAGE ACTIVATION; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL;

ATHEROSCLEROSIS; BLOOD VESSELS; DIABETES MELLITUS, TYPE 2; HUMANS; LIPOPROTEINS;

EID: 40749106211     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-008-0012-3     Document Type: Review

References (63)

1. Taskinen MR: Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003, 46:733-749.
2. Ginsberg HN: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006, 91:383-392.
3. Hokanson JE, Austin MA: Plasma triglyceride is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol: a meta analyses of population based prospective studies. J Cardiovasc Res 1996, 3:213-219.
4. Nordestgaard BG, Benn M, Schnohr P, et al.: Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. J Am Med Ass 2007, 298:299-308.
5. Bansal S, Buring JE, Rifai N, et al.: Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. J Am Med Assoc 2007, 298:309-316.
6. Eckel RH: Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD. Proc Nutr Soc 2007, 66:82-95.
7. Reaven GM: Metabolic syndrome. Pathophysiology and implications for management of cardiovascular disease. Circulation 2002, 106:286-288.
8. Rader DJ: Effect of insulin resistance, dyslipidemia, and intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007, 120: S12-S18.
9. Barter P: Managing diabetic dyslipidaemia - beyond LDL-C: HDL-C and triglycerides. Atheroscler Suppl 2006, 7:17-21.
10. Kontush A, Chapman MJ: Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev 2006, 58:342-374.
11. Lewis GF, Carpentier A, Adeli K, et al.: Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002, 23:201-229.
12. Frayn KN, Fielding BA, Karpe F: Adipose tissue fatty acid metabolism and cardiovascular disease. Curr Opin Lipidol 2005, 16:409-415.
13. Adiels M, Taskinen MR, Packard C, et al.: Overproduction of large VLDL particles is driven by increased liver fat content in man. Diabetologia 2006, 49:755-765.
14. Eriksson JW, Buren J, Svensson M, et al.: Postprandial regulation of blood lipids and adipose tissue lipoprotein lipase in type 2 diabetes patients and healthy control subjects. Atherosclerosis 2003, 166:359-367.
15. Shimizugawa T, Ono M, Shimamura M, et al.: ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 2002, 277:33742-33748.
16. Dallinga-Thie GM, Dullaart RP, van Tol A: Concerted actions of cholesteryl ester transfer protein and phospholipid transfer protein in type 2 diabetes: effects of apolipoproteins. Curr Opin Lipidol 2007, 18:251-257.
17. Barter PJ, Brewer HB, Jr, Chapman MJ, et al.: Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003, 23:160-167.
18. Vaisar T, Pennathur S, Green PS, et al.: Shotgun proteomics implicates protease inhibition and complement activation in the anti-inflammatory properties of HDL. J Clin Invest 2007, 117:746-756.
19. Rezaee F, Casetta B, Levels JH, et al.: Proteomic analysis of high-density lipoprotein. Proteomics 2006, 6:721-730.
20. Nobecourt E, Jacqueminet S, Hansel B, et al.: Defective antioxidative activity of small dense HDL3 particles in type 2 diabetes: relationship to elevated oxidative stress and hyperglycaemia. Diabetologia 2005, 48:529-538.
21. Schaefer EJ, Asztalos BF: Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Curr Opin Lipidol 2006, 17:394-398.
22. Miida T, Miyazaki O, Nakamura Y, et al.: Analytical performance of a sandwich enzyme immunoassay for pre beta 1-HDL in stabilized plasma. J Lipid Res 2003, 44:645-650.
23. Kruijt JK, Groen AK, Van Berkel TJ, et al.: Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 2007, 12:6429-6439.
24. Tall AR: An overview of reverse cholesterol transport. Eur Heart J 1998, 19(Suppl A):A31-A35.
25. Barter P: The inflammation: lipoprotein cycle. Atheroscler Suppl 2005, 6:15-20.
26. Navab M, Imes SS, Hama SY, et al.: Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 1991, 88:2039-2046.
27. Lusis AJ: Atherosclerosis. Nature 2000, 407:233-241.
28. Goldberg IJ, Dansky HM: Diabetic vascular disease: an experimental objective. Arterioscler Thromb Vasc Biol 2006, 26:1693-1701.
29. Nobecourt E, Davies MJ, Brown BE, et al.: The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007, 50:643-653.
30. Hoang A, Murphy AJ, Coughlan MT, et al.: Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007, 50:1770-1779.
31. Curtiss LK, Witztum JL: Plasma apolipoproteins AI, AII, B, CI, and E are glucosylated in hyperglycemic diabetic subjects. Diabetes 1985, 34:452-461.
32. Brown BE, Rashid I, Van Reyk DM, et al.: Glycation of low-density lipoprotein results in the time-dependent accumulation of cholesteryl esters and apolipoprotein B-100 protein in primary human monocyte-derived macrophages. FEBS J 2007, 274:1530-1541.
33. Ikonen E: Mechanisms for cellular cholesterol transport: defects and human disease. Physiol Rev 2006, 86:1237-1261.
34. Oram JF, Heinecke JW: ATP-binding cassette transporter A1: a cell cholesterol exporter that protects against cardiovascular disease. Physiol Rev 2005, 85:1343-1372.
35. Duong M, Collins HL, Jin W, et al.: Relative contributions of ABCA1 and SR-BI to cholesterol efflux to serum from fibroblasts and macrophages. Arterioscler Thromb Vasc Biol 2006, 26:541-547.
36. Attie AD: ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 2007, 32:172-179.
37. Gelissen IC, Harris M, Rye KA, et al.: ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006, 26:534-540.
38. Vaughan AM, Oram JF: ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 2005, 280:30150-30157.
39. Brooks-Wilson A, Marcil M, Clee SM, et al.: Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999, 22:336-345.
40. Marcil M, Brooks-Wilson A, Clee SM, et al.: Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999, 354:1341-1346.
41. Vedhachalam C, Duong PT, Nickel M, et al.: Mechanism of ATP-binding cassette transporter AI (ABCA1)-mediated cellular lipid efflux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem 2007, 282:25123-25130.
42. Wang N, Tall AR: Regulation and mechanisms of ATP-binding cassette transporter Al-mediated cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003, 23:1178-1184.
43. Yancey PG, Bortnick AE, Kellner-Weibel G, et al.: Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 2003, 23:712-719.
44. Wang MD, Franklin V, Marcel YL: In vivo reverse cholesterol transport from macrophages lacking ABCA1 expression is impaired. Arterioscler Thromb Vasc Biol 2007, 27:1837-1842.
45. Wang N, Lan D, Chen W, et al.: ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci U S A 2004, 101:9774-9779.
46. Wang X, Collins HL, Ranalletta M, et al.: Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007, 117:2216-2224.
47. Vergeer M, Hovingh GK, Vissers MN, et al.: Heterozygosity for a mutation in the extracellular domain of SR-B1 is associated with high HDL cholesterol levels in a family of Caucasian descent. Circulation 2006, 115:abstract 1340.
48. Fielding CJ, Fielding PE: Molecular physiology of reverse cholesterol transport. J Lipid Res 1995, 36:211-228.
49. Clark RW, Ruggeri RB, Cunningham D, et al.: Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006, 47:537-552.
50. Jauhiainen M, Metso J, Pahlman R, et al.: Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993, 268:4032-4036.
51. Von Eckardstein A, Jauhiainen M, Huang YD, et al.: Phospholipid transfer protein mediated conversion of high density lipoproteins generates b1-HDL. Biochim Biophys Acta 1996, 1301:255-262.
52. Guerin M, Le Goff W, Lassel TS, et al.: Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol 2001, 21:282-288.
53. de Vries R, Borggreve SE, Dullaart RPF: Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus. Clin Lab 2003, 49:601-613.
54. Bhatnagar D, Durrington PN, Kumar S, et al.: Plasma lipoprotein composition and cholesteryl ester transfer from high density lipoproteins to very low density and low density lipoproteins in patients with non-insulin-dependent diabetes mellitus. Diabet Med 1996, 13:139-144.
55. de Vries R, Perton FG, Dallinga-Thie GM, et al.: Plasma cholesteryl ester transfer is a determinant of intima-media thickness in type 2 diabetic and nondiabetic subjects: role of CETP and triglycerides. Diabetes 2005, 54:3554-3559.
56. Desrumaux C, Athias A, Bessède G, et al.: Mass concentration of plasma phospholipid transfer protein in normolipidemic, type IIa hyperlipidemic, type IIb hyperlipidemic, and non-insulin-dependent diabetic subjects as measured by a specific ELISA. Arterioscler Thromb Vasc Biol 1999, 19:266-275.
57. Riemens SC, van Tol A, Sluiter WJ, et al.: Plasma phospholipid transfer protein activity is related to insulin resistance: impaired acute lowering by insulin in obese type II diabetic patients. Diabetologia 1998, 41:929-934.
58. Tan KC, Shiu SW, Wong Y, et al.: Plasma phospholipid transfer protein activity and subclinical inflammation in type 2 diabetes mellitus. Atherosclerosis 2005, 178:365-370.
59. de Vries R, Groen AK, Perton FG, et al.: Increased cholesterol efflux from cultured fibroblasts to plasma from hypertriglyceridemic type 2 diabetic patients: roles of pre beta-HDL, phospholipid transfer protein and cholesterol esterification. Atherosclerosis 2007, [Epub ahead of print.]
60. Hirayama S, Miida T, Miyazaki O, et al.: Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007, 30:1289-1291.
61. Chetiveaux M, Lalanne F, Lambert G, et al.: Kinetics of prebeta1 HDL and alphaHDL in type II diabetic patients. Eur J Clin Invest 2006, 36:29-34.
62. Dullaart RPF, van Tol A: Role of phospholipid transfer protein and prebeta-high density lipoproteins in maintaining cholesterol efflux from Fu5AH cells to plasma from insulin-resistant subjects. Scand J Clin Lab Invest 2001, 61:69-74.
63. Watanabe H, Soderlund S, Soro-Paavonen A, et al.: Decreased high-density lipoprotein (HDL) particle size, pre-beta-, and large HDL subspecies concentration in Finnish low-HDL families: relationship with intima-media thickness. Arterioscler Thromb Vasc Biol 2006, 26:897-902.